Lista de obras - Louis Chesler - Dominio Público Uruguay

Abstract 1426: MiRNA expression profiling of the murine GTML medulloblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs

artículo científico publicado en 2012

Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells

artículo científico publicado en 2011

Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging

artículo científico publicado en 2010

Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo

artículo científico publicado en 2011

Abstract 4757: The ALK-F1174L mutation accelerates MYCN-driven tumorigenesis in a murine transgenic neuroblastoma model

artículo científico publicado en 2011

Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma

artículo científico publicado en 2014

Abstract IA13: Targeting the dependence of N-Myc on interaction with Aurora-A with small molecules

artículo científico publicado en 2013

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro

artículo científico publicado en 2017

Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. ⬇️

artículo científico publicado en 2017

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

artículo científico publicado en 2012

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

artículo científico publicado en 1996

Challenges to curing primary brain tumours

scientific article published on 01 August 2019

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

artículo científico publicado en 2015

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

artículo científico publicado en 2015

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

artículo científico publicado en 2017

Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

artículo científico publicado en 2012

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer

artículo científico publicado en 2015

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

artículo científico publicado en 2018

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma

artículo científico publicado en 2012

From class waivers to precision medicine in paediatric oncology.

artículo científico publicado en 2017

Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma ⬇️

artículo científico publicado el 21 de septiembre de 2011

Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus

artículo científico publicado en 2018

Identification of a neuronal transcription factor network involved in medulloblastoma development

artículo científico publicado en 2013

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach

artículo científico publicado en 2013

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

artículo científico publicado en 2017

Implementation of mechanism of action biology-driven early drug development for children with cancer.

artículo científico publicado en 2016

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

scientific article published on 12 August 2019

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

artículo científico publicado en 2022

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase

artículo científico publicado en 1994

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

artículo científico publicado en 2016

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

artículo científico publicado en 2006

Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma

artículo científico publicado en 2014

Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography

artículo científico publicado en 2019

MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

artículo científico publicado en 2019

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma

artículo científico publicado en 2018

Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma

artículo científico publicado en 2007

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

artículo científico publicado en 2018

Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma

artículo científico publicado en 2015

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

artículo científico publicado en 2014

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

artículo científico publicado en 2015

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

artículo científico publicado en 2013

Noninvasive MRI native T1 mapping detects response to MYCN-targeted therapies in the Th-MYCN model of neuroblastoma

artículo científico publicado en 2020

Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells ⬇️

artículo científico publicado en 2007

Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma

artículo científico publicado en 2015

Paraneoplasia, cancer development and immunity: what are the connections?

artículo científico publicado en 2014

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

artículo científico publicado en 2012

Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study

artículo científico publicado en 2011

Pleiotropic role for MYCN in medulloblastoma.

artículo científico publicado en 2010

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.

artículo científico publicado en 2017

Preclinical drug development for childhood cancer

artículo científico publicado en 2010

Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.

artículo científico publicado en 2017

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'

artículo científico publicado en 2019

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

artículo científico publicado en 2013

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors ⬇️

artículo científico publicado en 2016

Subclonal reconstruction of tumors by using machine learning and population genetics

scientific article published on 02 September 2020

Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic

artículo científico publicado en 2015

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

artículo científico publicado en 2016

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

artículo científico publicado en 2012

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

artículo científico publicado en 2011

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

artículo científico publicado en 2014

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

artículo científico publicado en 2015

Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma

artículo científico publicado en 2020

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs

artículo científico publicado en 2011

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.

artículo científico publicado en 2016

Lista de obras de Louis Chesler

Abstract 1426: MiRNA expression profiling of the murine GTML medulloblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs

Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells

Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging

Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo

Abstract 4757: The ALK-F1174L mutation accelerates MYCN-driven tumorigenesis in a murine transgenic neuroblastoma model

Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma

Abstract IA13: Targeting the dependence of N-Myc on interaction with Aurora-A with small molecules

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro

Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. ⬇️

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

Challenges to curing primary brain tumours

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma

From class waivers to precision medicine in paediatric oncology.

Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma ⬇️

Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus

Identification of a neuronal transcription factor network involved in medulloblastoma development

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma

Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography

MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma

Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma

Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.

Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

Noninvasive MRI native T1 mapping detects response to MYCN-targeted therapies in the Th-MYCN model of neuroblastoma

Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells ⬇️

Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma

Paraneoplasia, cancer development and immunity: what are the connections?

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study

Pleiotropic role for MYCN in medulloblastoma.

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.

Preclinical drug development for childhood cancer

Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors ⬇️

Subclonal reconstruction of tumors by using machine learning and population genetics

Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.